Tango Therapeutics Inc

NASDAQ:TNGX   3:59:51 PM EDT
5.54
+0.13 (+2.40%)
Earnings Announcements

Tango Therapeutics Reports First Quarter 2022 Financial Results And Provides Business Highlights

Published: 05/11/2022 11:18 GMT
Tango Therapeutics Inc (TNGX) - Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights.
Cash Position of $450 Million Expected to Support Advancing Discovery and Clinical Pipeline Into Second Half of 2024.
Tango Therapeutics - Qtrly Net Loss per Common Share Basic and Diluted $0.29.
Q1 Earnings per Share View $-0.28 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $5.66 Million
Adjusted EPS is expected to be -$0.32

Next Quarter Revenue Guidance is expected to be $5.66 Million
Next Quarter EPS Guidance is expected to be -$0.34

More details on our Analysts Page.